The mantle cell lymphoma (MCL) landscape is diverse, containing nine drugs that are aimed at a variety of targets, including CD20, Bruton’s tyrosine kinase (BTK), DNA, 26s proteasome, and phosphoinositide 3-kinase (PI3K).

The figure below displays a competitive assessment of the marketed and late-stage pipeline drugs for MCL, a sub-type of non-Hodgkin’s lymphoma. The drugs are scored according to their clinical and commercial attractiveness.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roche’s Rituxan (rituximab), with or without chemotherapy, is the standard-of-care regimen against which other agents are compared. While Rituxan possesses the highest clinical efficacy, it no longer possesses the highest commercial potential, as there are now rituximab biosimilars available in the US, the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), and Japan.

Competitive assessment of MCL drugs 

Mantle cell lymphoma therapies

Source: GlobalData. © GlobalData

The therapies with the highest commercial potential in MCL are BTK inhibitors: AbbVie and Johnson & Johnson’s (J&J’s) Imbruvica (ibrutinib) and AstraZeneca’s Calquence (acalabrutinib), which have demonstrated high efficacy in MCL.

Other agents, including Celgene’s Revlimid (lenalidomide), Teva’s Treanda (bendamustine), Takeda’s Velcade (bortezomib), TG Therapeutics’ pipeline agents ublituximab and umbralisib (also known as the U2 regimen), and AbbVie’s Venclexta (venetoclax tablets), rank similarly in terms of commercial and clinical attributes. The outlier is Pfizer’s Torisel (temsirolimus), which has not demonstrated much efficacy in MCL and is not approved for that indication in the US.